2025年3月12日 · Mepolizumab (Nucala) is a prescription medication FDA-approved for several eosinophil-related conditions including Hypereosinophilic Syndrome (HES), Eosinophilic …

Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic …

Learn more about NUCALA (mepolizumab), a maintenance treatment for patients with severe eosinophilic asthma. NUCALA is not used for sudden breathing problems.

2025年3月12日 · Nucala (mepolizumab) is a biologic therapy used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and …

2025年2月1日 · Mepolizumab injection is used with other medicines to treat severe asthma. It is given to patients whose asthma is not controlled with their current asthma medicines. It is also …

2008年3月19日 · Mepolizumab is a fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis …

2014年9月25日 · Patients were assigned to receive mepolizumab, a humanized monoclonal antibody against interleukin-5, which was administered as either a 75-mg intravenous dose or …

Mepolizumab injection is used along with other medications to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in certain children 6 years of age …

Mepolizumab, an anti-interleukin-5 monoclonal antibody, has demonstrated efficacy and safety in randomized controlled trials (RCTs). We aimed to strengthen the real-world evidence base for …

NUCALA (mepolizumab) for injection, for subcutaneous use Initial U.S. Approval: 2015 . INDICATIONS AND USAGE. NUCALA is an interleukin-5 antagonist monoclonal antibody …